In adult patients with CKD associated with T2D
Patients with progressing CKD associated with T2D need your help at every stage of their disease1,4
Not a real patient.
eGFR declined from
71 to 67 mL/min/1.73 m2
in the past year
Microalbuminuria: 150 mg/g†
Serum potassium: 3.8 mEq/L
Treated with a maximum
tolerated dose of an ARB
Together, eGFR and urinary protein (measured by UACR) show what could lie ahead for your patients
Colors reflect the ranking of adjusted relative risk from a categorical meta-analysis. Rank numbers 1 to 8=green; 9 to 14=yellow; 15 to 21=orange; 22 to 28=red.4
Adapted with permission from KDIGO. Levey AS, de Jong PE, Coresh J, et al. Chapter 2: Definition, identification, and prediction of CKD progression. Kidney Int Suppl. 2013;3(1):63-72. Accessed April 28, 2023. https://www.kisupplements.org/article/S2157-1716(15)31102-3/fulltext
Not a real patient.
eGFR declined from
62 to 58 mL/min/1.73 m2
in the past year
Microalbuminuria: 220 mg/g†
Serum potassium: 4.2 mEq/L
Treated with a maximum
tolerated dose of an ARB
Together, eGFR and urinary protein (measured by UACR) show what could lie ahead for your patients
Colors reflect the ranking of adjusted relative risk from a categorical meta-analysis. Rank numbers 1 to 8=green; 9 to 14=yellow; 15 to 21=orange; 22 to 28=red.4
Adapted with permission from KDIGO. Levey AS, de Jong PE, Coresh J, et al. Chapter 2: Definition, identification, and prediction of CKD progression. Kidney Int Suppl. 2013;3(1):63-72. Accessed April 28, 2023. https://www.kisupplements.org/article/S2157-1716(15)31102-3/fulltext
Not a real patient.
eGFR declined from
50 to 44 mL/min/1.73 m2
in the past year
Macroalbuminuria: 360 mg/g‡
Serum potassium: 4.4 mEq/L
Treated with a maximum
tolerated dose of an ARB
Together, eGFR and urinary protein (measured by UACR) show what could lie ahead for your patients
Colors reflect the ranking of adjusted relative risk from a categorical meta-analysis. Rank numbers 1 to 8=green; 9 to 14=yellow; 15 to 21=orange; 22 to 28=red.4
Adapted with permission from KDIGO. Levey AS, de Jong PE, Coresh J, et al. Chapter 2: Definition, identification, and prediction of CKD progression. Kidney Int Suppl. 2013;3(1):63-72. Accessed April 28, 2023. https://www.kisupplements.org/article/S2157-1716(15)31102-3/fulltext
*The FIDELIO-DKD and FIGARO-DKD trials were randomized, double-blind, placebo-controlled, multicenter trials of adult patients with CKD associated with T2D. In the FIDELIO-DKD trial, approximately 97% of patients were on an antidiabetic medication (insulin [64.1%], biguanides [44%], GLP-1 receptor agonists [7%], and/or SGLT2 inhibitors [5%]). Background therapies were similar in the FIGARO-DKD trial.1†Microalbuminuria can be defined as "moderately increased" with a UACR of 30-300 mg/g.4‡Macroalbuminuria can be defined as "severely increased" with a UACR >300 mg/g.4
ACR=albumin-to-creatinine ratio; ARB=angiotensin receptor blocker; CKD=chronic kidney disease; CV=cardiovascular; eGFR=estimated glomerular filtration rate; GLP-1=glucagon-like peptide-1; HF=heart failure; KDIGO=Kidney Disease: Improving Global Outcomes; MOA=mechanism of action; MOD=mechanism of disease; SGLT2=sodium-glucose cotransporter 2; T2D=type 2 diabetes; UACR=urine albumin-to-creatinine ratio.
KERENDIA is indicated to reduce the
risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)
Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium
Please read the Prescribing Information for KERENDIA.
References: 1. KERENDIA (finerenone) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; September 2022. 2. Afkarian M, et al. J Am Soc Nephrol. 2013;24(2):302-308. doi:10.1681/ASN.2012070718. 3. Rossing P, Epstein M. Am J Med. 2022;135(5):576-580. doi:10.1016/j.amjmed.2021.11.019. 4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Intl Suppl. 2013;3(1):1-150. doi:10.1038/kisup.2012.73.